ATP6V1B2 Research Notes

Gene overview

ATP6V1B2 encodes the non-catalytic B subunit of the V1 peripheral domain of the vacuolar-type H+-ATPase (V-ATPase), specifically the brain isoform (also known as subunit B2, the 58 kDa B subunit, or HO57). The V1 complex catalyzes ATP hydrolysis, with three non-catalytic B subunits alternating with three catalytic A subunits in the AB heterohexameric ring. The B subunit cannot independently hydrolyze ATP but is essential for assembly and function of the V1 complex.

Core function — V-ATPase non-catalytic B subunit

The B2 subunit is the non-catalytic component of the catalytic AB heterodimer. While the catalytic site is on subunit A (ATP6V1A), the B subunit contributes to the structural integrity and regulation of the catalytic hexameric ring and the overall V1 complex assembly.

PMID:33065002

PMID:2145275

Brain isoform vs. kidney isoform

ATP6V1B2 (B2) is the brain isoform of the B subunit, ubiquitously expressed. It was originally identified from human brain cDNA and is 90% identical at the amino acid level to the kidney isoform B1 (ATP6V1B1). The kidney isoform B1 is more specifically expressed in renal intercalated cells where it plays a critical role in urinary proton secretion; mutations in B1 cause distal renal tubular acidosis (dRTA).

PMID:2145275

ATP6V1B2 can partially compensate for B1 (ATP6V1B1) in renal intercalated cells under baseline conditions but cannot fully compensate under acid load.

[file:human/ATP6V1B2/ATP6V1B2-uniprot.txt "In renal intercalated cells, can partially compensate the lack of ATP6V1B1 and mediate secretion of protons (H+) into the urine under base-line conditions but not in conditions of acid load"]

Subcellular localizations

ATP6V1B2 is localized to:
- Apical cell membrane of kidney early distal nephron (PMID:29993276, experimental)
- Melanosome (PMID:12643545, proteomics of stage I-IV melanosomes)
- Cytoplasm (by similarity with rat B2)
- Synaptic vesicle membrane (by similarity with rat B2)
- Clathrin-coated vesicle membrane (by similarity)

PMID:29993276

Note: PMID:29993276 is primarily about B1 (ATP6V1B1), not B2. The paper notes that B2 is also expressed in TAL and DCT. The apical plasma membrane IDA annotation for ATP6V1B2 in GOA comes from this paper but is based on B1 antibody data showing B2 co-localization patterns.

Tissue distribution

ATP6V1B2 is the ubiquitously expressed B subunit. The kidney paper (PMID:29993276) shows that B2 is expressed in thick ascending limb (TAL) and distal convoluted tubule (DCT). The original 1990 paper (PMID:2145275) isolated B2 from brain, establishing the "brain isoform" nomenclature.

Melanosome localization

ATP6V1B2 was detected in early melanosomes by mass spectrometry (PMID:12643545). V-ATPase is required for melanosome acidification, which controls melanin biosynthesis.

PMID:12643545

Disease associations

DDOD (Deafness, congenital, with onychodystrophy, autosomal dominant, MIM:124480): Caused by dominant mutations in ATP6V1B2. Main feature is congenital sensorineural hearing loss with nail dystrophy or absence. Coniform teeth, selective tooth agenesis, and hand/foot abnormalities present in some patients. The founding mutation identified by PMID:24913193.

ZLS2 (Zimmermann-Laband syndrome 2, MIM:616455): Caused by dominant mutations in ATP6V1B2. Characterized by facial dysmorphism, gingival enlargement, hypoplasia or aplasia of terminal phalanges/nails, hypertrichosis, joint hyperextensibility, and hepatosplenomegaly. Some patients have intellectual disability with or without epilepsy. ZLS2 is caused by p.Arg485Pro variant (PMID:25915598). KCNH1 mutations cause the allelic Zimmermann-Laband syndrome type 1.

[PMID:25915598 paper: "Mutations in KCNH1 and ATP6V1B2 cause Zimmermann-Laband syndrome"]

Protein interactions

ATP6V1B2 interacts with WFS1 (Wolfram syndrome protein), as shown in UniProt INTERACTION records. It also interacts with HTT (huntingtin), NEFL (neurofilament light), GFAP, and JPH3 (junctophilin-3). The interaction with HTT-related proteins may be relevant to neurodegenerative disease pathomechanisms.

Annotation quality notes

• Three protein binding (GO:0005515) annotations from IPI evidence (PMID:25416956 proteomics interactome, PMID:32814053 neurodegeneration proteins interactome, PMID:34159380 SARS-CoV-2 Nsp2 interactome) should be MARK_AS_OVER_ANNOTATED.
• The apical plasma membrane IDA (PMID:29993276) annotation is primarily about the B1 isoform; B2 co-localization is noted but the study focused on B1. Annotation is valid but the evidence is weaker for B2 specifically.
• Regulation of macroautophagy (NAS, PMID:22982048) is an indirect downstream consequence of lysosomal acidification; the lipofuscin paper does not study ATP6V1B2 directly.
• Multiple Reactome TAS annotations for cytosol reflect V1-V0 disassembly; valid but non-core.
• Exosome HDA annotations are from high-throughput proteomics and likely reflect contamination.

Falcon deep research synthesis (2026-06-21)

Falcon deep research has now completed (file:human/ATP6V1B2/ATP6V1B2-deep-research-falcon.md,
22 citations). It corroborates the B2 (brain/ubiquitous, non-catalytic V1 subunit)
core above and adds disease-mechanism and interaction detail.

• Core confirmed. B2 is the non-catalytic partner in the AB catalytic
  heterodimers of the V1 hexamer (catalysis on subunit A); essential for V1
  assembly/integrity, not an independent ATPase. No change to calls.
• TBC1D24 interaction (Pepe 2025). TBC1D24 (mutated in DOORS syndrome/epilepsy)
  binds ATP6V1B2 and ATP6V1A to support V-ATPase assembly and organellar pH in
  neurons; its loss causes V1 mislocalization, impaired lysosomal acidification,
  defective autophagy and altered synaptic-vesicle recycling. Regulatory/assembly
  context (non-core).
• Disease via gain-of-function over-acidification (notable). Dominant
  ATP6V1B2 variants (recurrent truncating p.Arg506; missense) cause
  DDOD, DOORS, and Zimmermann-Laband syndromes. Mechanism is
  gain-of-function → lysosomal over-acidification* (lower lysosomal pH,
  substrate accumulation, blocked autophagic flux, abnormal lysosome morphology;
  Carpentieri 2024), with spiral-ganglion-neuron apoptosis driving progressive
  hearing loss and partial ATP6V1B1 compensation in hair cells (Qiu 2021). This is
  the opposite polarity to the ATP6V1B1/ATP6V0A4 loss-of-function dRTA, and worth
  noting when interpreting variant effects — but it does not change the normal B2
  function calls.

Net: no change to calls — B2 is the ubiquitous/brain non-catalytic V1 subunit
supporting V-ATPase assembly and organellar acidification.